These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29253743)

  • 21. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Pitarokoili K; Hellwig K; Lukas C; Gold R
    Mult Scler; 2017 Mar; 23(3):483-486. PubMed ID: 28260421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
    D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
    Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of natalizumab-associated PML with filgrastim.
    Stefoski D; Balabanov R; Waheed R; Ko M; Koralnik IJ; Sierra Morales F
    Ann Clin Transl Neurol; 2019 May; 6(5):923-931. PubMed ID: 31139690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
    Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
    Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
    Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
    Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
    van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
    Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab in Multiple Sclerosis: Long-Term Management.
    Clerico M; Artusi CA; Liberto AD; Rolla S; Bardina V; Barbero P; Mercanti SF; Durelli L
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
    J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
    [No Abstract]   [Full Text] [Related]  

  • 32. Improving risk-stratification of natalizumab-associated PML.
    Tugemann B; Berger JR
    Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L; Vijiaratnam N; Skibina O
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
    Miranda Acuña JA; Weinstock-Guttman B
    Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
    Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
    J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoking is not associated with higher prevalence of JC virus in MS patients.
    Auer M; Bsteh G; Hegen H; Di Pauli F; Wurth S; Berger T; Deisenhammer F
    Eur J Clin Microbiol Infect Dis; 2018 May; 37(5):907-910. PubMed ID: 29423619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations for characterizing the risk of PML in natalizumab-treated patients.
    Koendgen H; Ho PR; Chang I
    Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357
    [No Abstract]   [Full Text] [Related]  

  • 39. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
    Mahler C; Schumacher AM; Unterrainer M; Kaiser L; Höllbacher T; Lindner S; Havla J; Ertl-Wagner B; Patzig M; Seelos K; Neitzel J; Mäurer M; Krumbholz M; Metz I; Brück W; Stadelmann C; Merkler D; Gass A; Milenkovic V; Bartenstein P; Albert NL; Kümpfel T; Kerschensteiner M
    Brain; 2021 Oct; 144(9):2683-2695. PubMed ID: 33757118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Yap SM; McGuigan C
    Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.